98%
921
2 minutes
20
Post-stroke depression (PSD) is a common complication that worsens neurological recovery and increases mortality among stroke survivors, creating a significant burden on patients and families. While exercise interventions are known to alleviate depressive symptoms in mild stroke cases, the effects of traditional Chinese exercises on PSD have not been systematically reviewed. This study aimed to evaluate the clinical efficacy of traditional Chinese exercises in treating PSD. A comprehensive search of eight Chinese and English databases identified randomized controlled trials (RCTs) published up to July 2024. Data were independently screened, extracted, and analyzed using RevMan 5.3 and Stata 17, with heterogeneity assessed through sensitivity, subgroup, and meta-regression analyses. Ten RCTs involving 627 participants were included. Meta-analysis revealed that traditional Chinese exercises significantly reduced depressive symptoms and improved daily living abilities in PSD patients. Specifically, HAMD scores decreased [SMD = -1.40, 95% CI (-1.88, -0.92), < 0.00001], treatment efficacy improved [OR = 3.74, 95% CI (1.69, 8.28), = 0.001], FMA scores increased [MD = 6.22, 95% CI (4.12, 8.32), < 0.00001], and BI levels rose [MD = 4.95, 95% CI (2.96, 6.93), < 0.00001]. In conclusion, traditional Chinese exercises offer significant benefits in treating PSD, demonstrating both efficacy and safety. https://www.crd.york.ac.uk/PROSPERO/view/CRD42024574791.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125479 | PMC |
http://dx.doi.org/10.3389/fpubh.2025.1570878 | DOI Listing |
J Dermatolog Treat
December 2025
Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited.
Methods: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024.
Biomed Chromatogr
October 2025
Department of Rehabilitation, Nan'ao People's Hospital, Shenzhen, China.
Chrysotobibenzyl, a bioactive ingredient from Dendrobium chrysotoxum, exhibits potent anti-tumor activity. However, its metabolic profiles remain unelucidated. This study aimed to disclose the metabolic fates of chrysotobibenzyl using human liver fractions.
View Article and Find Full Text PDFBMC Psychiatry
September 2025
Department of Cardiovascular, The Second Affiliated Hospital of Nanchang University, No. 1 Minde Road, Jiangxi, Nanchang, 330006, China.
Int J Lab Hematol
September 2025
Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Background: T follicular helper (TFH) cell lymphoma is complex, and we hope to provide a new perspective for its diagnosis.
Methods: We analysed the immunophenotypes of 89 mature T-cell lymphomas, including 52 nodal lymphomas of TFH origin, as well as 32 benign lymph node samples and 30 healthy bone marrow samples, by flow cytometry (FCM).
Results: Among pan-T cell markers, CD4CD5CD3 is the typical pattern that distinguishes TFH lymphoma from other T-cell lymphomas.
Cytokine Growth Factor Rev
September 2025
Shandong University of Traditional Chinese Medicine, Jinan 250355, China; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, China. Electronic address:
This review summarizes the biological properties of key myokines (Irisin, Apelin, CLCF1, and Myostatin) and osteokines (Osteocalcin, Sclerostin, FGF23 and the RANKL/OPG system). This work provides an in-depth analysis of the age-related network imbalance mechanism characterized by "downregulation of protective factors (Irisin, CLCF1, and uncarboxylated Osteocalcin) - upregulation of pro-degenerative factors (Myostatin, Sclerostin, and FGF23) - inflammation-driven amplification", and reveals the mechanism by which this network imbalance contributes to the comorbidity of sarcopenia, osteoporosis, and neurodegenerative diseases. Furthermore, the review evaluates the intersecting regulatory networks and molecular pathways through which myo-osteogenic factors modulate neurotrophic factors (BDNF, NGF and GDNF), and proposes intervention strategies based on these intersecting regulatory networks.
View Article and Find Full Text PDF